Cyclopharm Ltd - Asset Resilience Ratio
Cyclopharm Ltd (CYC) has an Asset Resilience Ratio of 1.98% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CYC total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Cyclopharm Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Cyclopharm Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cyclopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Cyclopharm Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$1.23 Million | 1.98% |
| Total Liquid Assets | AU$1.23 Million | 1.98% |
Asset Resilience Insights
- Limited Liquidity: Cyclopharm Ltd maintains only 1.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cyclopharm Ltd Industry Peers by Asset Resilience Ratio
Compare Cyclopharm Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.44% |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332 |
Medical Distribution | 5.56% |
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998 |
Medical Distribution | 0.08% |
Annual Asset Resilience Ratio for Cyclopharm Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Cyclopharm Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.98% | AU$1.23 Million ≈ $868.47K |
AU$62.13 Million ≈ $43.96 Million |
-24.07pp |
| 2018-12-31 | 26.04% | AU$6.13 Million ≈ $4.34 Million |
AU$23.54 Million ≈ $16.65 Million |
-11.13pp |
| 2017-12-31 | 37.17% | AU$8.69 Million ≈ $6.15 Million |
AU$23.38 Million ≈ $16.54 Million |
+9.20pp |
| 2016-12-31 | 27.97% | AU$4.59 Million ≈ $3.25 Million |
AU$16.41 Million ≈ $11.61 Million |
-- |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more